Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France
← catalyst calendarNCT06504615 · readout in 742 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
208actual
Sites
2
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-10 | actual | When the study began enrolling |
| Primary completion | 2028-08-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-08-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Adenocarcinoma
- Gastro-esophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma (EAC)
- Esophageal Squamous Cell Carcinoma (ESCC)
Intervention
- Drug: nivolumab + chemotherapy
Primary outcome
what the primary-completion date above is the date OFOverall survival (OS)
measured Day 0 and months 2-3, 4-6, 8-9, 12, 18, 24, 30 and 36
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed